1. Dose Response and Pharmacokinetics of Tofacitinib (CP‐690, 550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis. (22nd May 2013) Authors: Tan, H; Gupta, P; Harness, J; Wolk, R; Chapel, S; Menter, A; Strober, B; Langley, RG; Krishnaswami, S; Papp, KA Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 2:Number 5(2013) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight. (20th March 2017) Authors: Hutmacher, MM; Papp, K; Krishnaswami, S; Ito, K; Tan, H; Wolk, R; Valdez, H; Mebus, C; Rottinghaus, ST; Gupta, P Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 5(2017) Page Start: 322 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis. Issue 6 (21st June 2017) Authors: Checchio, T; Ahadieh, S; Gupta, P; Mandema, J; Puig, L; Wolk, R; Valdez, H; Tan, H; Krishnaswami, S; Tallman, A; Kaur, M; Ito, K Journal: Clinical pharmacology & therapeutics Issue: Volume 102:Issue 6(2017) Page Start: 1006 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗